Clinical Trials Logo

Filter by:
NCT ID: NCT01049464 Recruiting - Atrial Fibrillation Clinical Trials

Magnesium Sulphate for Treatment of New Onset Atrial Fibrillation in Medical Intensive Care Unit Patient

EMSAF
Start date: January 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy of Magnesium sulphate for the rate and rhythm control of the new onset (within 48 hours) atrial fibrillation in the hemodynamically unstable patients, admitted in the medical intensive care unit patients.

NCT ID: NCT01049217 Terminated - Neuropathy Clinical Trials

Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy

Start date: April 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of pregabalin compared to placebo in reducing neuropathic pain associated with HIV neuropathy.

NCT ID: NCT01048853 Active, not recruiting - Clinical trials for Cervical Adenocarcinoma

Conservative Surgery in Treating Patients With Low-Risk Stage IA2 or IB1 Cervical Cancer

Start date: August 25, 2009
Phase: N/A
Study type: Interventional

This clinical trial studies conservative surgery in treating patients with low-risk stage IA2 or IB1 cervical cancer. Conservative surgery is a less invasive type of surgery for early stage cervical cancer and may have fewer side effects and improve recovery.

NCT ID: NCT01048073 Completed - Clinical trials for Lower Respiratory Tract Infection

Non-influenza Etiologies of Acute Respiratory Illness in Southeast Asia

Start date: May 2010
Phase: N/A
Study type: Observational

Acute respiratory infection (ARI) constitutes a leading cause of morbidity, hospitalization and mortality worldwide. The most common etiologic agents of ARI's, especially in children, are viruses. The study objective is to determine the viral and bacterial etiologies of ARIs in patients with lower respiratory tract infection in South East Asia. This is a laboratory based surveillance study, in which the archival specimens from hospitalized patients will be tested for respiratory pathogens other than influenza viruses Standard descriptive statistics will be used to present the findings

NCT ID: NCT01044810 Completed - Clinical trials for Treatment Failure, HIV or AIDS

Effectiveness of Efavirenz-based Regimen in HIV-1-infected Patients With Nevirapine Hypersensitivity

Start date: January 2010
Phase: N/A
Study type: Observational

The primary objective of this study is to compare the effectiveness of EFV-based regimens in HIV-1-infected patients who; (1) were previously allergic to NVP and stopped all ARV simultaneously; (2) were previously allergic to NVP and continued the other NRTIs for a period of time, i.e. "staggered interruption"; and (3) started EFV-based regimens as an initial regimen (as controlled group).

NCT ID: NCT01044095 Completed - Influenza Clinical Trials

Study of Seasonal Influenza Vaccine Against H5N1 Avian Influenza Virus

Start date: November 2009
Phase: N/A
Study type: Interventional

This will be a randomized, open-label, pilot feasibility study of four 2-dose vaccine regimens in healthy volunteers using two commercially available seasonal influenza vaccines to compare immune responses and in vitro cross-reactivity against H5N1. Vaccine doses will be spaced by approximately 8 weeks to allow for optimal prime boost conditions. Humoral, cellular and secretory immune responses will be measured 2 and 4 weeks after each vaccine dose and compared with baseline values.

NCT ID: NCT01042769 Completed - Clinical trials for Diabetes Mellitus Type 2

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Start date: February 2010
Phase: Phase 3
Study type: Interventional

This double-blind, parallel, two-arm study will evaluate the potential to reduce cardiovascular risk, the tolerability and long-term safety profile of aleglitazar compared to placebo on top of standard care in patients with recent acute coronary syndrome (ACS) and type 2 diabetes mellitus. Patients will be randomized to receive either aleglitazar or placebo once daily as oral doses. The study will last until at least 950 events occur, but time on study treatment will be for at least 2.5 years.

NCT ID: NCT01042457 Completed - Lupus Nephritis Clinical Trials

Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis

Start date: May 2009
Phase: Phase 3
Study type: Interventional

To evaluate therapeutic response to MMF treatment in patients with International Society of Nephrology/Renal Pathology Society (ISN/RPS) class III or IV lupus nephritis. Mycophenolic acid levels at 1-hour post dose will be monitored monthly up to 6 months.

NCT ID: NCT01041963 Recruiting - Clinical trials for Continuous Ambulatory Peritoneal Dialysis

The Effect of Enalapril and Losartan on Peritoneal Membrane in Continuous Ambulatory Peritoneal Dialysis Patients

Start date: June 2009
Phase: Phase 4
Study type: Interventional

A prospective, randomized, open-label, Single-center clinical trial to determine whether Enalapril or Enalapril plus Losartan effect on Peritoneal membrane transportation.

NCT ID: NCT01039948 Completed - Lung Cancer Clinical Trials

A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer

Start date: December 2009
Phase: Phase 1/Phase 2
Study type: Interventional

During Phase 1b portion, there will be a dose-escalation of AV-299 (formerly SCH 900105) in combination with the recommended dose of gefitinib in subjects with NSCLC or advanced solid tumor. The objective is to determine the safety, tolerability, dose limiting toxicity (DLT) and recommended Phase 2 dose (RP2D) in combination with gefitinib for the Phase 2 portion. The Phase 2 is an open-label, 2-arm, randomized study designed to compare the combination of AV-299 (formerly SCH900105) and gefitinib versus gefitinib alone in clinically selected Asian subjects with previously untreated lung adenocarcinoma who have a high likelihood of harboring activating EGFR mutations. Subjects who progress after initial disease control in the gefitinib alone arm may crossover to the combination arm.